Skip to main content
4BASEBIO PLC logo

4BASEBIO PLC — Investor Relations & Filings

Ticker · 4BB ISIN · GB00BMCLYF79 LEI · 213800E2DX9EAIUNCB30 IL Manufacturing
Open in API
Filings indexed 92 across all filing types
Latest filing 2025-06-25 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL 4BB

About 4BASEBIO PLC

https://www.4basebio.com/

4BASEBIO PLC is a biotechnology company specializing in the design and manufacturing of synthetic DNA for next-generation therapeutics and vaccines. The company provides high-purity, Good Manufacturing Practice (GMP) grade nucleic acid products, including its proprietary opDNA®, as a plasmid-free alternative to traditional methods. Its technology is engineered to accelerate development timelines, enhance safety, and improve manufacturing scalability for applications in genetic medicine, including mRNA vaccines, viral vector-based gene therapies, and gene editing. 4basebio's solutions aim to eliminate production bottlenecks and de-risk manufacturing for partners in the pharmaceutical and biotechnology sectors.

Recent filings

Filing Released Lang Actions
4basebio Plc - Exercise of Options
Share Issue/Capital Change Classification · 1% confidence The document announces the exercise of EMI options by employees, resulting in the issuance of 13,000 new ordinary shares. It explicitly discusses the resulting change in the total number of ordinary shares with voting rights (15,509,393) and mentions this figure will be used by shareholders for calculating disclosure requirements under the FCA's Disclosure and Transparency Rules. This action directly relates to a change in the company's share capital structure due to the issuance of new shares following option vesting/exercise. This aligns best with the 'Share Issue/Capital Change' definition (SHA). It is not a general financing announcement (CAP), nor is it a director's dealing (DIRS).
2025-06-25 English
4basebio Plc - Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' concerning an acquisition or disposal of voting rights in 4BASEBIO PLC. This form is used to report changes in significant share ownership that cross certain notification thresholds. This directly matches the definition for Major Shareholding Notification (MRQ), which covers 'Notification of changes in significant share ownership levels (crossing thresholds)'. The document is a regulatory disclosure of insider/major shareholder activity, not a general earnings release, annual report, or management presentation.
2025-06-17 English
4basebio Plc - Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' concerning an acquisition of voting rights in 4basebio Plc, specifically detailing the resulting situation where a shareholder (DELPHI Unternehmensberatung Aktiengesellschaft) crossed a notification threshold, resulting in a holding of 33.013180% of voting rights. This type of mandatory disclosure regarding changes in significant share ownership thresholds is classified as a Major Shareholding Notification.
2025-06-17 English
4basebio Plc - Final Results and Notice of AGM
Report Publication Announcement Classification · 1% confidence The document is titled "# 4basebio Plc - Final Results and Notice of AGM". It explicitly states it is reporting the "Final Results for the financial year ended 31 December 2024" and includes a full Consolidated Statement of Profit or Loss and a Consolidated Statement of Financial Position. This content strongly indicates a comprehensive annual financial report. Although it mentions the 'Notice of AGM' and the AGM presentation, the core of the document is the detailed annual financial performance review, which aligns best with the Annual Report (10-K) definition, even if the company is AIM-listed and might file a UK equivalent. Given the comprehensive nature and the inclusion of full financial statements for the year, 10-K is the closest fit among the provided codes for a full annual report. The document length is substantial (over 31k characters), ruling out RPA/RNS based on the 'MENU VS MEAL' rule.
2025-05-27 English
4basebio Plc - Director Dealing
Director's Dealing Classification · 1% confidence The document is titled 'Director Dealing' and explicitly details share purchases made by the CEO, Dr. Heikki Lanckriet. It includes a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR) table, which is the standard format for reporting insider trades. This aligns perfectly with the definition for Director's Dealing (DIRS).
2025-04-04 English
4basebio Plc - 4basebio Receives GMP Licence for its UK DNA Manufacturing Facility
Regulatory Filings Classification · 1% confidence The document is a press release announcing that 4basebio PLC has received a GMP (Good Manufacturing Practice) license for its UK DNA manufacturing facility. It is a corporate announcement regarding operational progress and regulatory certification, which does not fit into specific financial reporting categories like 10-K, IR, or DIV. As it is a general regulatory announcement regarding company operations, it falls under the 'Regulatory Filings' (RNS) category.
2025-04-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.